TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. (RNAZ) Net Income & Profit History
Annual & trailing net income, net margin, YoY change, and peer profitability context.
RNAZ · net income · updated Jun 9, 2026
Core profitability metrics
RNAZ · net income · margin · TTM · CAGRNet income was −$34.7M for FY2025 (fiscal year ending 2025-12-31), down 106.9% year-over-year. Net profit margin was —.
Annual net income history
▸ FMP /income-statement · Annual · RNAZ net income history · RNAZ profit margin
Annual net income data
Net income vs peers (Healthcare)
About Net Income & Methodology
TransCode Therapeutics, Inc. (RNAZ) reported net income of −$34.7M for FY2025 (fiscal year ending 2025-12-31), down 106.9% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.
TransCode Therapeutics, Inc. has not yet achieved annual profitability based on available data (8 fiscal years). The company has reported net losses across all available periods.
TransCode Therapeutics, Inc.'s net profit margin was — for FY2025, based on the latest annual results.
Investors sometimes search for "TransCode Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from RNAZ net income. Data sourced from FMP /income-statement · US GAAP · USD.
Frequently asked questions
RNAZ net income · 4 questionsTransCode Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $34.7M for FY2025.
▸ Source: FMP /income-statement · GAAP · TransCode Therapeutics, Inc. · TransCode Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026